Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric
antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma …

PURPOSE Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric
antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell …

Introduction CD19 directed CAR T cells have shown potent activity in relapsed/refractory
(R/R) aggressive B-cell lymphomas (B-NHL) leading to the FDA approval of axicabtagene …

Introduction CD19 directed CAR T cells have potent activity in relapsed/refractory (R/R)
aggressive B-cell lymphomas (B-NHL) leading to the FDA approval of axicabtagene …

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are autologous anti-CD19
chimeric antigen receptor T (CAR T) cell therapies for the treatment of patients with …

Background The prognosis of patients with early relapsed or refractory large B-cell
lymphoma after the receipt of first-line chemoimmunotherapy is poor. Methods In this …

Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric
antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell …

Introduction Axi-cel is an autologous anti-CD19 CAR T-cell therapy approved by the US FDA
10/18/2017, for the treatment of adults with relapsed or refractory (r/r) large B-cell lymphoma …

Background: Axi-cel is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell
therapy approved for the treatment of patients (pts) with relapsed/refractory large B cell …

Background In an analysis of the primary outcome of this phase 3 trial, patients with early
relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel) …